Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 4/20 | 0.56 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.45 |
| ▸ | CD38 | P28907 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ACP1 | P24666 | 2/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4832245 | 0.84 | NCF1 (0.52) | NCF1UTS2RKMT2AKDM4E | |
| SCHEMBL8105729 | 0.81 | CD38 (0.59) | NCF1HTR6CD38SLC2A1 | |
| Hydrochloric Acid SCHEMBL3062395 | 0.80 | CD38 (0.58) | NCF1HTR6CD38SLC2A1 | |
| SCHEMBL3059015 | 0.80 | CD38 (0.61) | NCF1CD38CYP2C19MEN1KMT2A | |
| SCHEMBL4632716 | 0.79 | IGF1R (0.56) | NCF1UTS2RMEN1KMT2AKDM4E | |
| SCHEMBL14288479 | 0.78 | HTT (0.52) | NCF1MEN1KMT2AKDM4E | |
| SCHEMBL4834020 | 0.78 | NCF1 (0.52) | NCF1KMT2AKDM4E | |
| SCHEMBL4829967 | 0.76 | NCF1 (0.42) | NCF1HTR6UTS2RMEN1KMT2A | |
| SCHEMBL4834067 | 0.76 | NCF1 (0.53) | NCF1KDM4E | |
| SCHEMBL3056723 | 0.75 | ACP1 (0.62) | NCF1CD38CYP2C19MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320989-B2 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-20080004312-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. | 2008-01-03 | — | — | US | disclosed |
| US-7265122-B2 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20050054850-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054850-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | UTS2R, GPR17, NTSR2 | NCF1 1285/4885HTR6 618/4885UTS2R 1/4885 |
| US-20080004312-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | UTS2R, GPR17, NTSR2 | NCF1 1285/4885HTR6 618/4885UTS2R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.